Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
24
PharmaGap Inc. is pleased to announce results from the initial testing of its lead cancer drug GAP-107B8 by the U.S. National Cancer Institute (NCI).
Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company's proprietary ADC technology.
Cell Therapeutics, Inc. (CTI) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non- Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
17
GlaxoSmithKline (GSK) and Genmab A/S announced today top-line results from an international multi-center study of Arzerra(TM) (ofatumumab) in rituximab refractory follicular non-Hodgkin's lymphoma (NHL).
13
Primary intraocular lymphomas (PIOLs) arise from the retina and rarely from the uvea. Those arising from the retina, which were recently suggested be renamed primary retinal lymphoma (PRL) and which are formally known as ocular reticulum cell sarcomas, comprise a subset of primary central nervous system lymphoma (PCNSL).1,2 It involves the retina, vitreous, and optic nerve head- with or without central nervous system (CNS) involvement.
Keryx Biopharmaceuticals, Inc. announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in relapsed or relapsed / refractory multiple myeloma patients previously treated with bortezomib (VELCADE ).
The International Myeloma Foundation (IMF)-- supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians--today said newly published data may provide a possible genetic link between environmental toxins and bone disease in multiple myeloma.
04
Nearly a third (31%) of all bendamustine-treated patients saw all clinical evidence of their advanced chronic lymphocytic leukaemia (CLL) disappear when used as a first-line treatment option, according to the results of a large new multicentre phase III study published online by the Journal of Clinical Oncology today. Only 2% of patients treated with chlorambucil (the standard treatment) in the study achieved the same results.
Exercise may combat the debilitating fatigue that patients with leukemia experience, University of North Carolina at Chapel Hill researchers said.
03
Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has received Orphan Drug Designation from the European Medicines Agency (EMEA) for BiTE antibody blinatumomab (MT103) for acute lymphoblastic leukemia (ALL). Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy cancer cells.
We care about your feedback. Let us know how we can improve your CancerCompass experience.